Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 5/20 | 0.62 |
| ▸ | MEN1 | O00255 | 4/20 | 0.62 |
| ▸ | CASP6 | P55212 | 1/20 | 0.57 |
| ▸ | GFER | P55789 | 1/20 | 0.57 |
| ▸ | PKM | P14618 | 4/20 | 0.54 |
| ▸ | GAA | P10253 | 2/20 | 0.53 |
| ▸ | LMNA | P02545 | 1/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.51 |
| ▸ | NPC1 | O15118 | 2/20 | 0.51 |
| ▸ | RAB9A | P51151 | 2/20 | 0.51 |
| ▸ | MAPT | P10636 | 1/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.51 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.51 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.51 |
| ▸ | HPGD | P15428 | 1/20 | 0.50 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12792965 | 0.87 | ALDH1A1 (0.68) | KMT2AMEN1PKMGAALMNA | |
| SCHEMBL14477863 | 0.85 | KMT2A (0.70) | KMT2AMEN1PKMGAALMNA | |
| SCHEMBL14925231 | 0.85 | PKM (0.55) | KMT2AMEN1PKMLMNAALDH1A1 | |
| SCHEMBL1870003 | 0.85 | PKM (0.55) | KMT2AMEN1PKMGAALMNA | |
| SCHEMBL25442190 | 0.84 | KMT2A (0.63) | KMT2AMEN1PKMGAALMNA | |
| SCHEMBL11306227 | 0.84 | PKM (0.69) | KMT2AMEN1PKMALDH1A1NPC1 | |
| SCHEMBL19563410 | 0.84 | KMT2A (0.62) | KMT2AMEN1PKMGAALMNA | |
| SCHEMBL2836564 | 0.84 | KMT2A (0.62) | KMT2AMEN1PKMGAALMNA | |
| SCHEMBL18711518 | 0.84 | PKM (0.71) | KMT2AMEN1PKMGAALMNA | |
| SCHEMBL14590548 | 0.83 | ALDH1A1 (0.67) | KMT2AMEN1PKMGAALMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230242496-A1 | SOX11 INHIBITORS FOR TREATING MANTLE CELL LYMPHOMA | ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI (US) | 2023-08-03 | — | — | US | disclosed |
| US-20230242496-A1 | SOX11 INHIBITORS FOR TREATING MANTLE CELL LYMPHOMA | ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI (US) | 2023-08-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230242496-A1 | SOX11 INHIBITORS FOR TREATING MANTLE CELL LYMPHOMA | BCL6, SOX18, BCL3 | KMT2A 578/4885MEN1 2558/4885CASP6 981/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.